VANDA PHARMACEUTICALS INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
VANDA PHARMACEUTICALS INC. (VNDA) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $49.13 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-11-07
- VANDA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $49.13M, a 18.87% increase year-over-year.
- VANDA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $47.35M, a 12.59% increase year-over-year.
- VANDA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $43.59M, a 16.51% increase year-over-year.
- VANDA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $44.28M, a 15.77% increase year-over-year.
- VANDA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $165.08M, a 13.06% increase from fiscal 2016.
- VANDA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $146.02M, a 32.83% increase from fiscal 2015.
- VANDA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $109.92M, a 751.54% increase from fiscal 2014.
- VANDA PHARMACEUTICALS INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $12.91M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-09-30 | $49.13M 10-Q · filed 2018-11-07 | $96.48M derived: sum of 2 quarters · filed 2018-11-07 | $140.08M 10-Q · filed 2018-11-07 | $184.35M derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-06-30 | $47.35M 10-Q · filed 2018-08-02 | $90.94M 10-Q · filed 2018-08-02 | $135.22M derived: sum of 3 quarters · filed 2018-08-02 | $176.55M derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-03-31 | $43.59M 10-Q · filed 2018-05-02 | $87.87M derived: sum of 2 quarters · filed 2018-05-02 | $129.20M derived: sum of 3 quarters · filed 2018-11-07 | $171.26M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-12-31 | $44.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $85.61M derived: sum of 2 quarters · filed 2018-11-07 | $127.67M derived: sum of 3 quarters · filed 2018-11-07 | $165.08M 10-K · filed 2018-02-15 |
| 2017-09-30 | $41.34M 10-Q · filed 2018-11-07 | $83.39M derived: sum of 2 quarters · filed 2018-11-07 | $120.81M 10-Q · filed 2018-11-07 | $159.05M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $42.06M 10-Q · filed 2018-08-02 | $79.47M 10-Q · filed 2018-08-02 | $117.72M derived: sum of 3 quarters · filed 2018-08-02 | $156.20M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | $37.41M 10-Q · filed 2018-05-02 | $75.66M derived: sum of 2 quarters · filed 2018-05-02 | $114.14M derived: sum of 3 quarters · filed 2018-05-02 | $150.17M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $38.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $76.73M derived: sum of 2 quarters · filed 2018-02-15 | $112.75M derived: sum of 3 quarters · filed 2018-02-15 | $146.02M 10-K · filed 2018-02-15 |
| 2016-09-30 | $38.48M 10-Q · filed 2017-11-08 | $74.51M derived: sum of 2 quarters · filed 2017-11-08 | $107.77M 10-Q · filed 2017-11-08 | $139.62M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $36.03M 10-Q · filed 2017-08-03 | $69.29M 10-Q · filed 2017-08-03 | $101.14M derived: sum of 3 quarters · filed 2018-02-15 | $129.48M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $33.26M 10-Q · filed 2017-05-03 | $65.11M derived: sum of 2 quarters · filed 2018-02-15 | $93.45M derived: sum of 3 quarters · filed 2018-02-15 | $121.04M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $31.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $60.19M derived: sum of 2 quarters · filed 2018-02-15 | $87.78M derived: sum of 3 quarters · filed 2018-02-15 | $109.92M 10-K · filed 2018-02-15 |
| 2015-09-30 | $28.34M 10-Q · filed 2016-11-03 | $55.93M derived: sum of 2 quarters · filed 2016-11-03 | $78.08M 10-Q · filed 2016-11-03 | $84.10M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $27.58M 10-Q · filed 2016-07-28 | $49.73M 10-Q · filed 2016-07-28 | $55.75M derived: sum of 3 quarters · filed 2017-02-17 | $61.08M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $22.15M 10-Q · filed 2016-05-05 | $28.17M derived: sum of 2 quarters · filed 2017-02-17 | $33.50M derived: sum of 3 quarters · filed 2017-02-17 | $35.06M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $6.02M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $11.35M derived: sum of 2 quarters · filed 2017-02-17 | $12.91M derived: sum of 3 quarters · filed 2017-02-17 | $12.91M 10-K · filed 2017-02-17 |
| 2014-09-30 | $5.33M 10-Q · filed 2015-11-04 | $6.89M derived: sum of 2 quarters · filed 2015-11-04 | $6.89M 10-Q · filed 2015-11-04 | |
| 2014-06-30 | $1.56M 10-Q · filed 2015-07-31 | $1.56M 10-Q · filed 2015-07-31 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $0.00 derived: sum of 2 quarters · filed 2013-02-26 | $1.54M derived: sum of 3 quarters · filed 2013-02-26 | $5.29M 10-K · filed 2013-02-26 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $1.54M derived: sum of 2 quarters · filed 2011-11-07 | $5.29M 10-Q · filed 2011-11-07 | |
| 2010-06-30 | $1.54M 10-Q · filed 2011-08-05 | $5.29M 10-Q · filed 2011-08-05 | ||
| 2009-12-31 | $1.98M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |